nach oben

Erschienen in:

29.05.2012 | Aktuell

Neue Antikörpertherapie halbiert Schubrate

Multiple Sklerose

verfasst von: Thomas Müller

Einloggen, um Zugang zu erhalten

Silberstein SD et al. Evidence-based guideline update: Pharmakologic treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Society. Neurology 2012;78;1337–1345PubMedView Article
Holland S et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Society. Neurology 2012;78;1346–1353PubMedView Article
Evers S et al. EFNS guideline on the drug treatment of migraine — revisedreport of an EFNS task force. Eur J Neurol 2009:16;968–981PubMedView Article
Im Internet unter www. http://www.dgn.org/
Cohen J et al. Efficacy and safety results from comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis II (CARE-MS II): A phase 3 study in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy“ AAN 2012 S01.004

Titel: Neue Antikörpertherapie halbiert Schubrate
Multiple Sklerose
verfasst von: Thomas Müller
Publikationsdatum: 29.05.2012
Verlag: Urban and Vogel
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 5/2012
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-012-0179-7

18.04.2024 | Arterielle Hypertonie | Nachrichten